|
|
|
|
Tuesday, August 27, 2019
Trovagene Inc. (TROV)
Progressing Prostate Cancer Data in Small Number of Patients
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Data presentation at APCC. Trovagene presented data from the Phase 2 Study of
Onvansertib in combination with Zytiga in patients with metastatic castration-resistant prostate cancer (mCRPC) at the 20th Asia-Pacific Prostate Cancer Conference. The data showed that two out of the four patients who tested positive for androgen receptor splice variant 7 (AR-V7) achieved the primary endpoint of disease control. As presented in ASCO, AR-V7 has been associated with poor prognosis and hormone therapy resistance in mCRPC patients (based on results from a prospective-blinded study (PROPHECY). - Still early to speculate clinical benefit. We believe it is still early to speculate
Onvansertib’s clinical efficacy in patients with mCRPC. We recognize the strong…
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.